CYR-064 for Loss of Smell
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called CYR-064 (a form of theophylline) to determine its safety and effectiveness for people who have lost their sense of smell. Participants will receive either CYR-064 or a placebo (a non-active substance) as a nasal solution for 24 weeks. The goal is to compare the effectiveness of CYR-064 to the placebo. Suitable candidates for this trial are those who have difficulty smelling, have no structural issues in their nasal cavity, and are willing to self-administer the treatment. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial requires participants to stop using any over-the-counter or prescription medications administered intranasally, except for nasal saline. Other medications may need to be stopped if the investigator believes they could affect safety or compliance with the study.
Is there any evidence suggesting that CYR-064 is likely to be safe for humans?
Research shows that CYR-064, a nasal spray, is being tested to improve the sense of smell. In earlier studies, participants used CYR-064 for 24 weeks to assess its safety and effectiveness. Although data remains limited, ongoing studies aim to learn more about how well participants tolerate the treatment.
Since the current trial is in Phase 2, earlier trials have provided some evidence of its safety. This suggests the treatment is likely well-tolerated, but more information is needed to fully understand any possible side effects. Remember, CYR-064 is still under investigation, so it is important to consider that research is ongoing when evaluating safety.12345Why do researchers think this study treatment might be promising for loss of smell?
Most treatments for loss of smell typically involve steroids or olfactory training. CYR-064 stands out because it is delivered as a nasal solution, allowing for direct application to the nasal passages, which could enhance its effectiveness. Researchers are excited about CYR-064 because it targets the underlying issues more directly than systemic treatments, potentially leading to quicker and more effective recovery of the sense of smell. Additionally, CYR-064 is self-administered, offering convenience and ease of use for patients.
What evidence suggests that CYR-064 might be an effective treatment for loss of smell?
Research shows that CYR-064 may help improve the sense of smell. In this trial, participants will receive either a nasal solution of CYR-064 at one of two doses or a placebo. Previous studies found that people using CYR-064 reported better smell scores than those using a placebo. This nasal spray is being tested to help those who have lost their sense of smell, especially after viral infections. Some early results suggest that CYR-064 might also help restore taste. As research continues, more will be learned about its effectiveness and safety.12346
Who Is on the Research Team?
Mas Takashima, MD
Principal Investigator
The Methodist Hospital Research Institute
Are You a Good Fit for This Trial?
This trial is for men and women aged 18-65 who've lost their sense of smell but don't have any nasal blockages or diseases causing it. They must be able to take the study drug themselves and follow the trial's procedures.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either CYR-064 or placebo nasal solution twice a day for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CYR-064
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cyrano Therapeutics, Inc.
Lead Sponsor